• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

游离前列腺特异性抗原检测性能特征的荟萃分析。

A meta-analysis of the performance characteristics of the free prostate-specific antigen test.

作者信息

Lee Richard, Localio A Russell, Armstrong Katrina, Malkowicz S Bruce, Schwartz J Sanford

机构信息

Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York 10021, USA.

出版信息

Urology. 2006 Apr;67(4):762-8. doi: 10.1016/j.urology.2005.10.052. Epub 2006 Apr 5.

DOI:10.1016/j.urology.2005.10.052
PMID:16600352
Abstract

OBJECTIVES

To conduct a meta-analysis of the diagnostic performance of the percent free prostate-specific antigen (%fPSA) test in determining prostate cancer status and to assess its value in helping to decide whether to biopsy the prostate.

METHODS

Articles identified through a MEDLINE search were included if they presented adequate original primary data to calculate a receiver operating characteristic (ROC) curve in subjects possessing histopathologically verified diagnoses. Articles containing subjects with concurrent, non-prostate-related genitourinary conditions were excluded. Percent free PSA sensitivity, specificity, ROC curves, and positive likelihood ratios were calculated for all PSA ranges and for the reflex range of PSA between 4 and 10 ng/mL.

RESULTS

Among the 41 studies, containing 19,643 subjects, area under the curve for %fPSA was 0.70 for all PSA levels, decreasing to 0.68 in the reflex range. A test cutoff of 20% would lead to 92% sensitivity and 23% specificity. Positive likelihood ratios ranged from 1.0 to 4.0, exceeding 2.0 at %fPSA of 15% or less. Within the reflex range, however, likelihood ratios exceeded 2.0 only at %fPSA of 7% or less.

CONCLUSIONS

Percent free PSA can be a useful adjunct to PSA for primary prostate cancer screening only under certain defined situations. In the "gray zone," or reflex range, of PSA testing, %fPSA improves clinical information only when levels reach extreme values.

摘要

目的

对游离前列腺特异性抗原百分比(%fPSA)检测在确定前列腺癌状态方面的诊断性能进行荟萃分析,并评估其在帮助决定是否对前列腺进行活检方面的价值。

方法

如果通过MEDLINE检索识别出的文章提供了足够的原始主要数据,以便在具有组织病理学确诊诊断的受试者中计算受试者工作特征(ROC)曲线,则纳入这些文章。排除包含患有并发的、与前列腺无关的泌尿生殖系统疾病受试者的文章。计算了所有PSA范围以及4至10 ng/mL的PSA反射范围内的游离PSA百分比敏感性、特异性、ROC曲线和阳性似然比。

结果

在41项研究(包含19,643名受试者)中,所有PSA水平下%fPSA的曲线下面积为0.70,在反射范围内降至0.68。20%的检测临界值将导致92%的敏感性和23%的特异性。阳性似然比范围为1.0至4.0,在%fPSA为15%或更低时超过2.0。然而,在反射范围内,只有在%fPSA为7%或更低时似然比才超过2.0。

结论

游离PSA百分比仅在某些特定情况下可作为PSA用于原发性前列腺癌筛查的有用辅助手段。在PSA检测的“灰色区域”或反射范围内,只有当%fPSA水平达到极值时,它才能改善临床信息。

相似文献

1
A meta-analysis of the performance characteristics of the free prostate-specific antigen test.游离前列腺特异性抗原检测性能特征的荟萃分析。
Urology. 2006 Apr;67(4):762-8. doi: 10.1016/j.urology.2005.10.052. Epub 2006 Apr 5.
2
The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.前列腺特异性抗原(PSA)与前列腺体积之比(PSA密度)作为一项参数,用于提高对PSA值在<4 ng/mL范围内前列腺癌的检测。
Cancer. 2005 Sep 1;104(5):993-1003. doi: 10.1002/cncr.21267.
3
Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.与总前列腺特异性抗原相比,复合前列腺特异性抗原在检测前列腺癌时能显著提高特异性。
J Urol. 2000 May;163(5):1476-80.
4
Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.比较游离前列腺特异性抗原(PSA)、复合PSA和总PSA的几种组合在诊断有泌尿系统症状患者前列腺癌中的作用。
Urology. 2004 Jun;63(6):1100-3; discussion 1103-4. doi: 10.1016/j.urology.2004.01.056.
5
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.在总前列腺特异性抗原范围为4.0至10.0 ng/ml的男性中,评估游离前列腺特异性抗原用于前列腺癌早期检测的情况。
J Urol. 2003 Sep;170(3):723-6. doi: 10.1097/01.ju.0000086940.10392.93.
6
Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?前列腺特异性抗原和游离前列腺特异性抗原在前列腺癌早期检测中的应用:联合检测能否提高检测效果?
Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1640-5.
7
Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.用于前列腺癌早期检测的各种前列腺特异性抗原比值的比较评估。
BJU Int. 2004 May;93(7):970-4; discussion 974. doi: 10.1111/j.1464-410X.2003.04762.x.
8
Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.对于总前列腺特异性抗原(PSA)在2.5至20 ng/ml之间的男性,复合前列腺特异性抗原密度在检测前列腺癌方面优于其他PSA衍生物:一项前瞻性多中心研究的结果。
Eur Urol. 2005 Mar;47(3):302-7. doi: 10.1016/j.eururo.2004.10.009. Epub 2004 Dec 1.
9
PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy.当代采用扩展活检时,PSA相关标志物在前列腺癌及高级别疾病检测中的应用
Urol Oncol. 2008 Mar-Apr;26(2):166-70. doi: 10.1016/j.urolonc.2007.05.030. Epub 2007 Nov 26.
10
Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.血清中游离前列腺特异性抗原的电泳亚形式作为前列腺癌诊断中有前景的诊断工具。
Urology. 2007 Feb;69(2):320-5. doi: 10.1016/j.urology.2006.09.066.

引用本文的文献

1
Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer.游离前列腺特异抗原与总前列腺特异抗原的比值作为转移性去势抵抗性前列腺癌生存生物标志物的研究
BJU Int. 2025 Aug;136(2):329-335. doi: 10.1111/bju.16751. Epub 2025 Apr 25.
2
Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps.前列腺癌筛查:证据、正在进行的试验、政策及知识空白。
BMJ Oncol. 2023 Apr 20;2(1):e000039. doi: 10.1136/bmjonc-2023-000039. eCollection 2023.
3
Single‑center, retrospective, evaluator‑blinded, pilot and pivotal clinical trials: Assessing the mirCaP Kit (hsv2‑miR‑H9/hsa‑miR‑3659) as a diagnostic marker for prostate cancer in patients with PSA levels in the gray zone.
单中心、回顾性、评估者盲法、先导性和关键性临床试验:评估mirCaP检测试剂盒(hsv2‑miR‑H9/hsa‑miR‑3659)作为前列腺特异性抗原(PSA)水平处于灰色区间的前列腺癌患者诊断标志物的作用
Oncol Lett. 2024 Oct 23;29(1):23. doi: 10.3892/ol.2024.14770. eCollection 2025 Jan.
4
A Blood-Based Immune Gene Signature with Prognostic Significance in Localized Prostate Cancer.一种基于血液的免疫基因特征对局限性前列腺癌具有预后意义。
Cancers (Basel). 2023 Jul 20;15(14):3697. doi: 10.3390/cancers15143697.
5
UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging.更新 - 2022年加拿大泌尿外科协会关于前列腺癌筛查和早期诊断的建议 认可2021年安大略癌症护理关于前列腺多参数磁共振成像的指南。
Can Urol Assoc J. 2022 Apr;16(4):E184-E196. doi: 10.5489/cuaj.7851.
6
Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men.用于前列腺癌早期检测的液体生物标志物及其在非裔美国男性中应用的现有数据总结。
Prostate Cancer Prostatic Dis. 2022 Feb;25(2):180-186. doi: 10.1038/s41391-022-00507-8. Epub 2022 Mar 4.
7
A Predictive Model Based on Bi-parametric Magnetic Resonance Imaging and Clinical Parameters for Clinically Significant Prostate Cancer in the Korean Population.基于双参数磁共振成像和临床参数的韩国人群中临床显著前列腺癌的预测模型。
Cancer Res Treat. 2021 Oct;53(4):1148-1155. doi: 10.4143/crt.2020.1068. Epub 2020 Dec 31.
8
Biomarkers in the setting of benign prostatic hyperplasia-induced lower urinary tract symptoms: what an interventional radiologist needs to know.良性前列腺增生症所致下尿路症状的生物标志物:介入放射科医生需要了解的知识。
Br J Radiol. 2020 Oct 1;93(1114):20200484. doi: 10.1259/bjr.20200484. Epub 2020 Aug 6.
9
An electrochemical biosensor for prostate cancer biomarker detection using graphene oxide-gold nanostructures.一种用于前列腺癌生物标志物检测的电化学生物传感器,采用氧化石墨烯-金纳米结构。
Eng Life Sci. 2019 Feb 7;19(3):206-216. doi: 10.1002/elsc.201800093. eCollection 2019 Mar.
10
Diagnosis of prostate cancer.前列腺癌的诊断。
Asian J Urol. 2019 Apr;6(2):129-136. doi: 10.1016/j.ajur.2018.11.007. Epub 2019 Feb 14.